Judith Stirn holds an M.Sc. in Chemistry and is a PhD candidate at the Institute of Pharmacy and Molecular Biotechnology (University of Heidelberg, Germany) where she is developing syntheses and performing in-vitro characterizations of 5-HT2 ligands and prodrugs thereof. Her research interests include the design of ligands with higher receptor selectivity and the optimization of the pharmacokinetic profile of psilocin for clinical practice.